Nvidia is mentioned as an institutional investor that previously bought shares of Generate Biomedicines.
Source Post
The creator discusses Generate Biomedicines (GEN), highlighting its lead drug entering Phase 3 trials and i...
Jul 19, 2026
The creator discusses Generate Biomedicines (GEN), highlighting its lead drug entering Phase 3 trials and its strong cash position. Despite a recent earnings miss and stock drop, analysts from HC Wainwright and Morgan Stanley raised price targets, indicating a bullish outlook based on the company's potential and financial stability.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.